Development of a Bioassay for Anti Tumor Activity of Biological Response Modifiers of the Reticuloendothelial Stimulant Class: Reproducibility of the Bioassay
- 1 January 1981
- journal article
- Published by Taylor & Francis in Journal of Immunopharmacology
- Vol. 3 (3-4) , 385-396
- https://doi.org/10.3109/08923978109031069
Abstract
Intravenously administered DiLuzio glucan, Wellcome C. parvum, and Glaxo BCG caused dose dependent increases in the tumor cell loss from the lungs of C57BL/6J and DBA/2J mice challenged respectively with intravenous 125IuDR labelled B16 or T 1699 mammary carcinoma cells. The results were reproducible with respect to the optimal doses and the magnitudes and shapes of the dose response curves.Keywords
This publication has 11 references indexed in Scilit:
- Development of a bioassay for the antitumor activity of biological response modifiers of the reticuloendothelial stimulant classCancer Immunology, Immunotherapy, 1981
- Comparative tumor‐inhibitory and anti‐bacterial activity of soluble and particulate glucanInternational Journal of Cancer, 1979
- Past, present and future of the synthetic immunoadjuvant MDP and its analogsBiochemical Pharmacology, 1978
- ANAPHYLACTIC REACTION TO INTRALESIONAL B.C.G.The Lancet, 1978
- THE EMPLOYMENT OF GLUCAN AND GLUCAN ACTIVATED MACROPHAGES IN THE ENHANCEMENT OF HOST RESISTANCE TO MALIGNANCIES IN EXPERIMENTAL ANIMALSPublished by Elsevier ,1976
- Immunotherapy of melanoma with BCG: Two fatalities following intralesional injectionCancer, 1975
- BCG and CancerNew England Journal of Medicine, 1974
- BCG and CancerNew England Journal of Medicine, 1974
- Complications of BCG Immunotherapy in Patients with CancerNew England Journal of Medicine, 1973
- Counting and sizing of tumor metastases in experimental oncologyInternational Journal of Cancer, 1966